CREATE Medicines raises $122M in Series B to advance in vivo CAR-T pipeline

CREATE Medicines announced the closing of its $122 million Series B funding round, which will support advancement of the Massachusetts-based biotech’s in vivo CAR clinical programs.

To date, CREATE has dosed more than 50 patients across its in vivo CAR clinical programs — the largest clinical dataset in the field — generating the translational foundation that informs development across both autoimmune disease and oncology. The company's proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines.

CREATE’s lead autoimmune program, CRT-402, is a next generation CD19 targeted in vivo CAR-T therapy. It has demonstrated deep and durable B cell depletion in non-human primates, with the potential to enable immune reset through the flexibility of repeat dosing. The company is also advancing a dual CAR CD19 x BCMA directed therapy designed to broaden therapeutic reach across refractory autoimmune indications. In oncology, early clinical data from the company’s MT-303 program in frontline hepatocellular carcinoma has demonstrated a compelling response profile.

The funding round was co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current members of CREATE’s investor syndicate.